Long-acting GHRH analogue
CJC-1295
A long-acting growth-hormone-releasing hormone analogue with clear human biomarker activity but no established clinical benefit for popular body-composition or recovery claims.
Also known as CJC 1295 · CJC-1295 DAC · CJC-1295 with DAC
01 · Evidence profile
One molecule, four evidence questions
Human studies measured hormone responses, not durable patient outcomes.
Randomized studies show sustained GH and IGF-1 biomarker effects in healthy adults.
Short studies exist, while FDA identifies serious adverse-event and impurity concerns.
CJC-1295 with DAC, without DAC, salts, and combinations are often discussed imprecisely.
02 · Identity
What it is
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone designed to extend biological activity. Online discussions often blur distinct forms, including references to CJC-1295 with or without a drug-affinity-complex modification.
03 · Product identity
The molecule is not the finished product.
CJC-1295 with a drug-affinity-complex modification is not interchangeable with products marketed as 'no DAC,' modified GRF 1-29, or unspecified compounded combinations.
None identified in the United States.
- No FDA-approved indication
04 · Evidence snapshot
What the evidence can and cannot say
Two randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults found sustained increases in growth hormone and IGF-1 after CJC-1295. A separate human study found increased trough and mean GH secretion with preserved pulsatility. These are real pharmacodynamic findings.
Biomarker changes do not establish better body composition, injury recovery, sleep, vitality, or longevity. The published human work does not provide a replicated clinical-outcome basis for those popular claims, and long-term safety remains insufficiently characterized.
05 · Claim check
Three claims under the lens
“CJC-1295 can raise GH and IGF-1 in healthy adults.”
Randomized human studies reported sustained hormone increases. This supports a biomarker effect, not a patient benefit.
- Evidence basis
- Human pharmacology
- Scope
- Short-term GH and IGF-1 pharmacodynamic responses in the healthy adults studied.
“CJC-1295 builds muscle and burns fat in people.”
The identified trials were not designed to establish durable improvements in body composition or function.
- Evidence basis
- No reliable human outcome evidence
- Scope
- Clinical body-composition and functional outcomes, which the cited pharmacology studies did not test.
“All products called CJC-1295 are interchangeable.”
The literature and commercial market may refer to different molecular forms, salts, modifications, and combinations.
- Evidence basis
- Regulatory or product record
- Scope
- Products marketed as CJC-1295 with different forms, salts, modifications, combinations, or quality controls.
06 · Safety boundary
Before this becomes personal
FDA identifies immunogenicity and peptide-impurity concerns and reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. This guide does not translate research doses into personal use.
Growth-hormone-releasing factors and analogues are prohibited under the current WADA framework.
Reviewed 2026-07-23. This status is not personal clearance to compete.Check the governing record ↗07 · Sources
Check the primary record
08 · Provenance
Review history
Expanded alias, product-identity, and anti-doping context.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.